The conduct of COVID-19 vaccine trials in the context of a candidate vaccine being issued with Emergency Use Designation raises challenging ethical questions, including in relation to the use of placebo controls and unblinding of trial participants in current and future COVID-19 vaccine trials. This... policy brief was developed by the WHO Access to COVID-19 Tools (ACT) Accelerator Ethics & Governance Working Group, to provide guidance for researchers, sponsors, regulators, research ethics committees, and policy-makers, on these and related issues.
more
9 September 2020
In a snapshot, fair allocation of vaccines will occur in the following way:
An initial proportional allocation of doses to countries until all countries reach enough quantities to cover 20% of their population
This document is also available in Arabic | Chinese | French | R...ussian | Spanish | Portuguese
A follow-up phase to expand coverage to other populations. If severe supply constraints persist, a weighted allocation approach would be adopted, taking account of a country’s COVID threat and vulnerability.
The document is a final working document and may be adjusted in the future as new information about the vaccines and the epidemiology of COVID-19 becomes available.
more
first issued 18 August 2022
9 September 2020
In a snapshot, fair allocation of vaccines will occur in the following way:
An initial proportional allocation of doses to countries until all countries reach enough quantities to cover 20% of their population
This document is also available in Arabic | Chinese | French | R...ussian | Spanish | Portuguese
A follow-up phase to expand coverage to other populations. If severe supply constraints persist, a weighted allocation approach would be adopted, taking account of a country’s COVID threat and vulnerability.
The document is a final working document and may be adjusted in the future as new information about the vaccines and the epidemiology of COVID-19 becomes available.
more
17 Febr. 2022. As part of the “Strategy to Achieve Global COVID-19 Vaccination by mid-2022”, global targets of 40% population coverage by end of 2021 and 70% coverage by June 2022 have been set by the World Health Organization (WHO), to successfully prevent severe illness and deaths, minimize so...cial disruption and economic consequences of COVID-19, curtail the emergence of new SARS-CoV-2 variants of concern (VOCs) and ultimately control the pandemic.
more
How much protection does the current batch of COVID-19 vaccines provide us? Would you need a booster shot for new variants? What does science and evidence tell us about mass gatherings and the spread of COVID-19?
WHO’s Chief Scientist Dr Soumya Swaminathan explains in Science in 5 this week.
Geneva, 22 May 2023 – Gavi, the Vaccine Alliance today published a roadmap* outlining critical actions needed to ensure supply of oral cholera vaccine (OCV) is able to meet growing demand from countries. Released against a backdrop of a recent wave of cholera outbreaks around the world, the roadma...p forecasts the short-, mid- and long-term outlook for global cholera vaccine supply. Developed in consultation with a range of key Alliance partners, including WHO, UNICEF, the Global Taskforce for Cholera Control (GTFCC), and the Bill and Melinda Gates Foundation (BMGF), it describes how these organizations, manufacturers and countries can work together towards ensuring global OCV supply can support largescale preventive vaccination by 2026.
more
REG 174 INFORMATION FOR UK HEALTHCARE PROFESSIONALS
African Union and the Africa Centers for Disease Control and Prevention’s Africa Regulatory Taskforce has endorsed the Emergency Used Authorization for Janssen COVID-19 Vaccine
10 March 2021
Do the current batch of approved vaccines protect us from the Delta variant? What is the level of protection? If you can still get infected even after being fully vaccinated, then why should we vaccinate? WHO’s Chief Scientist Dr Soumya Swaminathan explains in Science in 5.
31 March 2021
This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
COVID-19 vaccines are safe, and getting v...accinated will help protect you against developing severe COVID-19 disease and dying from COVID-19. You may experience some mild side effects after getting vaccinated, which are signs that your body is building protection.
more
Overview
The aim of this guide is to support national immunization programme managers and others responsible for implementing human rabies vaccine programmes to:
inform policy discussions and operational planning for introducing or expanding rabies post-exposure prophylaxis (PEP) into a nationa...l immunization programme (e.g. through the national immunization programme, or other programmes); and
highlight considerations specific to rabies PEP for integration into existing systems, including for implementation, and monitoring and evaluation.
While the guide is mainly intended for programme managers and focuses on human vaccination, complementary animal health measures are highlighted where relevant given the zoonotic nature of rabies.
The guide was developed collaboratively with input from technical experts in rabies and immunization, vaccines and biologicals.
more
It can be difficult to know which sources of information you can trust. Learn more about finding credible vaccine information.
Updated 19 August 2021